ID

39547

Description

A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children; ODM derived from: https://clinicaltrials.gov/show/NCT01349829

Link

https://clinicaltrials.gov/show/NCT01349829

Keywords

Versions (1)
  1. 1/26/20 1/26/20 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

January 26, 2020

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Hepatitis A NCT01349829

English

Eligibility Hepatitis A NCT01349829

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
a male or female between (and including) 18 months to 47 months of age.
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
written informed consent obtained from the parent/legal guardian of the subject.
Description

Informed Consent Parent | Informed Consent Guardian

Data type

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C0030551
UMLS CUI [2,1]
C0021430
UMLS CUI [2,2]
C1274041
free of obvious health problems as established by medical history and/or clinical examination before entering the study
Description

Free of Health problem | Medical History | Clinical Examination

Data type

boolean

Alias
UMLS CUI [1,1]
C0332296
UMLS CUI [1,2]
C0018684
UMLS CUI [1,3]
C0033213
UMLS CUI [2]
C0262926
UMLS CUI [3]
C0031809
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
seropositive for anti-hav antibodies (>=10 miu/ml).
Description

Hepatitis A virus antibodies Seropositive | Hepatitis A virus antibody measurement

Data type

boolean

Alias
UMLS CUI [1,1]
C0062524
UMLS CUI [1,2]
C0521143
UMLS CUI [2]
C0201473
use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period and safety follow-up.
Description

Investigational New Drugs | Drugs, Non-Prescription | INVESTIGATIONAL VACCINES | Investigational New Drugs Planned | Non-Prescription Drugs Planned | INVESTIGATIONAL VACCINES Planned

Data type

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2]
C0013231
UMLS CUI [3]
C1875384
UMLS CUI [4,1]
C0013230
UMLS CUI [4,2]
C1301732
UMLS CUI [5,1]
C0013231
UMLS CUI [5,2]
C1301732
UMLS CUI [6,1]
C1875384
UMLS CUI [6,2]
C1301732
chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose (for corticosteroids, such as prednisone, or equivalent, >=0.5 mg/kg/day.
Description

Immunosuppressive Agents chronic | Biological Response Modifiers chronic | Adrenal Cortex Hormones By Inhalation allowed | Adrenal Cortex Hormones Local allowed | Prednisone By Inhalation U/day allowed | Prednisone Local U/day allowed | Equivalent U/day allowed

Data type

boolean

Alias
UMLS CUI [1,1]
C0021081
UMLS CUI [1,2]
C0205191
UMLS CUI [2,1]
C0005525
UMLS CUI [2,2]
C0205191
UMLS CUI [3,1]
C0001617
UMLS CUI [3,2]
C0205535
UMLS CUI [3,3]
C0683607
UMLS CUI [4,1]
C0001617
UMLS CUI [4,2]
C0205276
UMLS CUI [4,3]
C0683607
UMLS CUI [5,1]
C0032952
UMLS CUI [5,2]
C0205535
UMLS CUI [5,3]
C0456683
UMLS CUI [5,4]
C0683607
UMLS CUI [6,1]
C0032952
UMLS CUI [6,2]
C0205276
UMLS CUI [6,3]
C0456683
UMLS CUI [6,4]
C0683607
UMLS CUI [7,1]
C0205163
UMLS CUI [7,2]
C0456683
UMLS CUI [7,3]
C0683607
inhaled and local steroids are allowed.)
Description

ID.7

Data type

boolean

planned administration/ administration of a measles containing vaccine within 4 weeks prior to and after the first or booster dose of study vaccine.
Description

Measles Vaccine Planned | Measles Vaccine

Data type

boolean

Alias
UMLS CUI [1,1]
C0025010
UMLS CUI [1,2]
C1301732
UMLS CUI [2]
C0025010
previous vaccination against hepatitis a.
Description

Vaccination Previous Hepatitis A

Data type

boolean

Alias
UMLS CUI [1,1]
C0042196
UMLS CUI [1,2]
C0205156
UMLS CUI [1,3]
C0019159
any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection.
Description

Immunosuppression | Immunosuppression Suspected | Immunodeficiency | Immunodeficiency Suspected | HIV Infection

Data type

boolean

Alias
UMLS CUI [1]
C4048329
UMLS CUI [2,1]
C4048329
UMLS CUI [2,2]
C0750491
UMLS CUI [3]
C0021051
UMLS CUI [4,1]
C0021051
UMLS CUI [4,2]
C0750491
UMLS CUI [5]
C0019693
history of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
Description

Hypersensitivity Exacerbation | Allergic Reaction Exacerbation | Etiology Vaccine Component

Data type

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C4086268
UMLS CUI [2,1]
C1527304
UMLS CUI [2,2]
C4086268
UMLS CUI [3,1]
C0015127
UMLS CUI [3,2]
C0042210
UMLS CUI [3,3]
C1705248
major congenital defects or serious chronic illness.
Description

Congenital defects Major | Chronic disease Serious

Data type

boolean

Alias
UMLS CUI [1,1]
C0000768
UMLS CUI [1,2]
C0205164
UMLS CUI [2,1]
C0008679
UMLS CUI [2,2]
C0205404
acute disease at the time of enrolment
Description

Acute Disease

Data type

boolean

Alias
UMLS CUI [1]
C0001314
Back to the top of the page

Similar models

Eligibility Hepatitis A NCT01349829

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
a male or female between (and including) 18 months to 47 months of age.
boolean
C0001779 (UMLS CUI [1])
Informed Consent Parent | Informed Consent Guardian
Item
written informed consent obtained from the parent/legal guardian of the subject.
boolean
C0021430 (UMLS CUI [1,1])
C0030551 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2,1])
C1274041 (UMLS CUI [2,2])
Free of Health problem | Medical History | Clinical Examination
Item
free of obvious health problems as established by medical history and/or clinical examination before entering the study
boolean
C0332296 (UMLS CUI [1,1])
C0018684 (UMLS CUI [1,2])
C0033213 (UMLS CUI [1,3])
C0262926 (UMLS CUI [2])
C0031809 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Hepatitis A virus antibodies Seropositive | Hepatitis A virus antibody measurement
Item
seropositive for anti-hav antibodies (>=10 miu/ml).
boolean
C0062524 (UMLS CUI [1,1])
C0521143 (UMLS CUI [1,2])
C0201473 (UMLS CUI [2])
Investigational New Drugs | Drugs, Non-Prescription | INVESTIGATIONAL VACCINES | Investigational New Drugs Planned | Non-Prescription Drugs Planned | INVESTIGATIONAL VACCINES Planned
Item
use of any investigational or non-registered drug or vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period and safety follow-up.
boolean
C0013230 (UMLS CUI [1])
C0013231 (UMLS CUI [2])
C1875384 (UMLS CUI [3])
C0013230 (UMLS CUI [4,1])
C1301732 (UMLS CUI [4,2])
C0013231 (UMLS CUI [5,1])
C1301732 (UMLS CUI [5,2])
C1875384 (UMLS CUI [6,1])
C1301732 (UMLS CUI [6,2])
Immunosuppressive Agents chronic | Biological Response Modifiers chronic | Adrenal Cortex Hormones By Inhalation allowed | Adrenal Cortex Hormones Local allowed | Prednisone By Inhalation U/day allowed | Prednisone Local U/day allowed | Equivalent U/day allowed
Item
chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose (for corticosteroids, such as prednisone, or equivalent, >=0.5 mg/kg/day.
boolean
C0021081 (UMLS CUI [1,1])
C0205191 (UMLS CUI [1,2])
C0005525 (UMLS CUI [2,1])
C0205191 (UMLS CUI [2,2])
C0001617 (UMLS CUI [3,1])
C0205535 (UMLS CUI [3,2])
C0683607 (UMLS CUI [3,3])
C0001617 (UMLS CUI [4,1])
C0205276 (UMLS CUI [4,2])
C0683607 (UMLS CUI [4,3])
C0032952 (UMLS CUI [5,1])
C0205535 (UMLS CUI [5,2])
C0456683 (UMLS CUI [5,3])
C0683607 (UMLS CUI [5,4])
C0032952 (UMLS CUI [6,1])
C0205276 (UMLS CUI [6,2])
C0456683 (UMLS CUI [6,3])
C0683607 (UMLS CUI [6,4])
C0205163 (UMLS CUI [7,1])
C0456683 (UMLS CUI [7,2])
C0683607 (UMLS CUI [7,3])
ID.7
Item
inhaled and local steroids are allowed.)
boolean
Measles Vaccine Planned | Measles Vaccine
Item
planned administration/ administration of a measles containing vaccine within 4 weeks prior to and after the first or booster dose of study vaccine.
boolean
C0025010 (UMLS CUI [1,1])
C1301732 (UMLS CUI [1,2])
C0025010 (UMLS CUI [2])
Vaccination Previous Hepatitis A
Item
previous vaccination against hepatitis a.
boolean
C0042196 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0019159 (UMLS CUI [1,3])
Immunosuppression | Immunosuppression Suspected | Immunodeficiency | Immunodeficiency Suspected | HIV Infection
Item
any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (hiv) infection.
boolean
C4048329 (UMLS CUI [1])
C4048329 (UMLS CUI [2,1])
C0750491 (UMLS CUI [2,2])
C0021051 (UMLS CUI [3])
C0021051 (UMLS CUI [4,1])
C0750491 (UMLS CUI [4,2])
C0019693 (UMLS CUI [5])
Hypersensitivity Exacerbation | Allergic Reaction Exacerbation | Etiology Vaccine Component
Item
history of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
boolean
C0020517 (UMLS CUI [1,1])
C4086268 (UMLS CUI [1,2])
C1527304 (UMLS CUI [2,1])
C4086268 (UMLS CUI [2,2])
C0015127 (UMLS CUI [3,1])
C0042210 (UMLS CUI [3,2])
C1705248 (UMLS CUI [3,3])
Congenital defects Major | Chronic disease Serious
Item
major congenital defects or serious chronic illness.
boolean
C0000768 (UMLS CUI [1,1])
C0205164 (UMLS CUI [1,2])
C0008679 (UMLS CUI [2,1])
C0205404 (UMLS CUI [2,2])
Acute Disease
Item
acute disease at the time of enrolment
boolean
C0001314 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial